RECRUITING

Penn Medicine Healthy Heart

Talk to us

Conditions

HypertensionHyperlipidemias

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.

Official Title

Reducing Atherosclerotic Cardiovascular Disease (ASCVD) Through a Comprehensive Heart Disease Prevention Program (HDPP)

Quick Facts

Study Start:2024-03-11
Study Completion:2025-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06062394

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:35 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * On the Penn Medicine Primary Care Service Line registry
  2. * Last 2 Blood Pressure readings with Systolic Blood Pressure \>=140 from any outpatient encounter in the last 12 months AND
  3. * ASCVD dx OR ASCVD risk score ≥10% OR Diabetes dx OR A1c ≥6.5 in last year OR Diabetes registry OR Last LDL ≥190 in past five years AND
  4. * Not on a statinor PCSK9, Inclisiran OR on a Low-intensity/moderate-intensity statin) with LDL \>100
  1. * Patients on PCSK9 inhibitors
  2. * Documented statin allergy/ or intolerance in the EMR
  3. * Pregnancy
  4. * Breast feeding
  5. * Markedly shortened life expectancy including:
  6. 1. metastatic cancer
  7. 2. hospice
  8. 3. End Stage Renal Disease
  9. 4. Congestive Heart Failure
  10. 5. Dementia
  11. * Is a non-English speaker requiring a translator
  12. * Patients who do not have a cell phone

Contacts and Locations

Study Contact

Kayla Clark, MPH
CONTACT
215-746-4428
kayla.clark@pennmedicine.upenn.edu
Laurie Norton, MA, MBE
CONTACT
Laurie.Norton@pennmedicine.upenn.edu

Principal Investigator

Kevin Volpp, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania

Study Locations (Sites)

Penn Medicine
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: University of Pennsylvania

  • Kevin Volpp, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-11
Study Completion Date2025-06

Study Record Updates

Study Start Date2024-03-11
Study Completion Date2025-06

Terms related to this study

Additional Relevant MeSH Terms

  • Hypertension
  • Hyperlipidemias